415 related articles for article (PubMed ID: 30887876)
1. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
Ferris LK; Ott E; Jiang J; Hong HC; Li S; Han C; Baran W
J Dermatolog Treat; 2020 Mar; 31(2):152-159. PubMed ID: 30887876
[No Abstract] [Full Text] [Related]
2. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
4. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
[TBL] [Abstract][Full Text] [Related]
13. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
14. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
[TBL] [Abstract][Full Text] [Related]
15. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Gordon KB; Blauvelt A; Foley P; Song M; Wasfi Y; Randazzo B; Shen YK; You Y; Griffiths CEM
Br J Dermatol; 2018 Jan; 178(1):132-139. PubMed ID: 28940259
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
Paul C; Lacour JP; Tedremets L; Kreutzer K; Jazayeri S; Adams S; Guindon C; You R; Papavassilis C;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1082-90. PubMed ID: 25243910
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
Nemoto O; Hirose K; Shibata S; Li K; Kubo H
Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
